أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - phleum pratense - frostþurrkuð tungurótartafla - 75.000 sq-t

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - ceftazidimum inn - innrennslisstofn, lausn - 2 g

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - sýklalyf fyrir almenn nota, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

accord healthcare s.l.u. - entecavir - lifrarbólga b, langvarandi - veirueyðandi lyf til almennrar notkunar - entecavir accord is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. , alvarleg lifrarsjúkdóm. , fyrir bæði bætt og alvarleg lifrarsjúkdóm, þetta vísbending er byggt á rannsókn gögn í núkleósíð barnaleg sjúklinga með hbeag jákvæð og hbeag neikvæð hbv sýkingu. með tilliti til sjúklinga með lifrarbólgu b sem eru með lamivúdín. entecavir hvötum er einnig ætlað til meðferð langvarandi hbv sýkingu í núkleósíð barnaleg börn sjúklingar frá 2 til.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - margvísleg sclerosis - Ónæmisbælandi lyf - meðferð hjá fullorðnum sjúklingum með endurkomna mynd af margfeldisskaða (rms) með virkum sjúkdómum sem eru skilgreindar með klínískum eða hugsanlegum eiginleikum. meðferð fullorðinn sjúklinga með snemma aðal framsækið heila-og mænusigg (ppms) í varðar sjúkdómur lengd og stig fötlun, og með hugsanlegur lögun einkennandi æsandi virkni.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - natríum ertapenem - bakteríusýkingar - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 og 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratoires thea* - cefuroximum natríum - stungulyfsstofn, lausn - 50 mg

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - cefepimum díhýdróklóríð mónóhýdrat - stungulyfs-/innrennslisstofn og leysir, lausn - 1 g

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - cefepimum díhýdróklóríð mónóhýdrat - stungulyfs-/innrennslisstofn og leysir, lausn - 2 g

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon, s.a. - ceftriaxonum dínatríum - innrennslisstofn, lausn - 2000 mg